v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]    
Revenue $ 1,442 $ 2,170
Operating expenses:    
Cost of revenues 284 154
Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) 202,016 152,919
General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) 165,527 134,019
Total operating expenses 367,827 287,092
Gain on litigation settlement 392 0
Loss from operations (365,993) (284,922)
Change in fair value of investments (36,637) 19,125
Change in fair value of liability instruments 0 2,329
Interest income (36,922) (48,322)
Other expense, net 2,130 11,208
Loss before income taxes (294,564) (269,262)
Income tax (benefit) expense (3,958) 4,649
Net loss (290,606) (273,911)
Net loss attributable to noncontrolling interests (100,769) (50,556)
Net loss attributable to Roivant Sciences Ltd. $ (189,837) $ (223,355)
Net loss per common share - basic (in dollars per share) $ (0.26) $ (0.33)
Net loss per common share - diluted (in dollars per share) $ (0.26) $ (0.33)
Weighted average shares outstanding - basic (in shares) 720,776,739 680,286,922
Weighted average shares outstanding - diluted (in shares) 720,776,739 680,286,922